Needham Initiates Coverage On NewAmsterdam Pharma with Buy Rating, Announces Price Target of $36
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has initiated coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Buy rating and set a price target of $36.
August 28, 2024 | 10:46 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham has initiated coverage on NewAmsterdam Pharma with a Buy rating and a price target of $36, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100